Navigation Links
Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Date:5/10/2011

BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced results from a post hoc analysis of the RAPID 2 study, published in the Annals of Rheumatic Diseases, which showed Cimzia®, the only approved PEGylated anti-TNF, plus methotrexate (MTX) provided rapid relief from a broad range of symptoms associated with the burden of moderate to severe active rheumatoid arthritis (RA). Those adult patients treated with Cimzia® that achieved early responses were found to have an increased chance of achieving longer-term outcomes.  

''These data show that when administered with methotrexate, certolizumab pegol offers rapid relief across a broad range of rheumatoid arthritis symptoms and that relatively few patients need to be treated before at least one patient reports clinical benefits from the positive relief the treatment provides,'' said lead investigator Dr. Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology and Rheumatology, at Stanford University, California. ''By assessing patient-reported outcomes at early-stages of treatment we are able to predict late-stage clinical outcomes and treatment benefits for patients, providing great reassurance to both patients and their healthcare professionals.''

PROs were secondary efficacy endpoints in RAPID 2 and were used to measure the impact of treatment with certolizumab pegol versus placebo. Number needed to treat (NNT) analysis was used in these post hoc analyses to interpret the PRO results. The NNT determines the number of patients that need to be treated in order to obtain the benefit of interest in one additional patient; therefore, small NNTs indicate favorable treatment effects. NNTs and minimum clinically important differences (MCIDs, which determine clinically meaningful improvements) were evaluated.

In the RAPID 2 study, patients with active RA (by 1987 American College of Rheumatology [ACR] classification criteria) with inadequate responses to MTX th
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
2. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
3. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
4. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
5. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
6. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
7. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
8. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
11. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... published in the Proceedings of the National ... showed when ibrutinib (IMBRUVICA ® ) was combined ... of tumor growth was enhanced suggesting a greater ... cancers and solid tumors with the combination. IMBRUVICA ...
(Date:2/27/2015)... Securities lawyers at Dunnam & Dunnam ... (NASDAQ: SLXP ) in connection with a ... are encouraged to contact attorney Hamilton Lindley by ... upon the shareholder value of the transaction. Under terms ... $158.00 per share in cash. At least one analyst ...
(Date:2/27/2015)... , Feb. 27, 2015  Boston Scientific Corporation ... in the Barclays 2015 Annual Healthcare Conference on March ... Dan Brennan , executive vice president and ... president, Investor Relations, will participate in a 25-minute question ... analyst at approximately 1:05 p.m. ET. Following a 5-minute ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2
... DIEGO, May 7, 2012 Volcano Corporation (NASDAQ: ... therapy tools designed to enhance the diagnosis and treatment of ... be participating in the 11th Annual JMP Securities Research Conference ... Dahldorf, chief financial officer, will begin at 10:30 a.m., Pacific ...
... Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, ... (FDA) has lifted the clinical hold previously placed on ... patients with Pseudomonas lung infections. ... CF clinical trial population consisting of adult patients who ...
Cached Medicine Technology:Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections 2Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections 3
(Date:3/1/2015)... “ The Barrel Mill ” was featured on NewsWatch ... look at the latest and coolest technology products and services ... a technology expert, conducted the review and shared with viewers ... According to Home Distillation of Alcohol, it's understood that oak ... pretty cool product that’ll help anyone achieve a barrel aged ...
(Date:3/1/2015)... February 28, 2015 CrossFit Attollo is a ... are offering a special discount to new members. Now ... for a three month contract will receive their fourth month ... would cost members $440. The three month contract is ... and then the fourth month comes in at only $55. ...
(Date:2/28/2015)... In recent years Medical Marijuana has continuously ... as a way for them to expand their patient base ... medicine. Since the FDA still lists Cannabis as a Schedule ... licensed physicians that can help guide them when recommending ... in Santa Cruz, CA is a leader in the ...
(Date:2/28/2015)... February 28, 2015 In a recent ... of Game Change Athlete Development Services ... about the benefits of athlete development and player engagement ... the unique challenges that athletes face and how off-field ... success. , Fletcher became involved in athlete development issues ...
(Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
Breaking Medicine News(10 mins):Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3
... law suit filed against sunscreen manufacturers in California as they ... on the other hand still recommend the liberal use of ... (SPF) ratings nor the label on the products gives a ... not cause burning but do cause aging of the skin ...
... of marriages. // ,Pathology labs in the city have registered ... season. ,Rajesh Bose (name changed) got an HIV test ... But her parents thought I was a flirt," said Bose. "But when ... ,Not only men but prospective brides too are going in ...
... Roseborough et al., mitochondrial K-ATP channel opener, diazoxide, prevents ... are the common problems that occur during aortic surgery ... in neurological deficits. But the works of Roseborough et ... injuries. , The results of his work ...
... protein present in chronic inflammatory conditions called heat shock ... – which is associated with the immune responses, a ... ,The specific response has earlier been observed in juvenile ... the role of HSP60 in inflammatory myositis. Inflammatory myositis ...
... club, for people living with HIV/Aids, started by Luta Shaba, an ... country. // ,Shaba says she dreams of ... use recommended safe sex methods. She says many of her ... large social stigma attached to HIV/Aids. Her club is a huge ...
... a coordinated action plan to check the deteriorating sexual ... ,The plan by UN agencies, WHO and UN Population ... more than half a million women die during pregnancy ... annually. , ,"There is a really worrying rise ...
Cached Medicine News:Health News:New Way To Combat Spinal Cord Injury during Aortic Surgery 2Health News:Proteins – A New Way to Treat Children's Muscle Diseas 2
Provides bright output and rotating lens with ultra-seal for pneumatic otoscopy....
... delivers power and reliability with proprietary ... Diode side-pumping technology drives 2.5 W ... Spectra system, and active resonator temperature ... system reliability from your first treatment ...
Features soft, low friction sheath that extends beyond the tip....
Facilitates intubation of tracheal tubes....
Medicine Products: